Dr Reddys Lab drops after Q4 earnings

Image
Capital Market
Last Updated : May 14 2014 | 9:31 AM IST

Dr Reddy's Laboratories lost 2.16% to Rs 2,036 at 14:08 IST on BSE after consolidated net profit surged 66.58% to Rs 570.89 crore on 30.79% growth in total income to Rs 3503.04 crore in Q4 March 2013 over Q4 March 2012.

The company announced Q4 results during trading hours today, 14 May 2013.

Meanwhile, the S&P BSE Sensex was up 60.70 points or 0.31% at 19,752.37.

On BSE, 1.05 lakh shares were traded in the counter as against average daily volume of 15,375 shares in the past one quarter.

The stock hit a high of Rs 2,119.90 and a low of Rs 2,025 so far during the day. The stock had hit a record high of Rs 2,150.90 on Monday, 13 May 2013. The stock had hit a 52-week low of Rs 1,528 on 19 June 2012.

The stock outperformed the market over the past one month till 13 May 2013, surging 9.43% compared with the Sensex's 7.94% rally. The scrip had also outperformed the market in past one quarter, jumping 9.2% as against Sensex's 0.43% rise.

The large-cap company has equity capital of Rs 84.91 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories' consolidated net profit rose 17.62% to Rs 1677.62 crore on 21.78% growth in total income to Rs 11874.46 crore in the year ended 31 March 2013 (FY 2013) over the year ended 31 March 2012 (FY 2012).

Dr Reddys Laboratories' board of directors at a meeting held today, 14 May 2013, recommended final dividend of Rs 15 per share for FY 2013.

Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses -- pharmaceutical services and active ingredients, global generics and proprietary products -- Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 14 2013 | 2:05 PM IST

Next Story